КОМБИНАЦИЯ МЕМАНТИНА И МЕЛАТОНИНА ПРИ УМЕРЕННЫХ КОГНИТИВНЫХ НАРУШЕНИЯХ В ПОЖИЛОМ ВОЗРАСТЕ: ВОЗМОЖНЫЕ КЛИНИЧЕСКИЕ ПЕРСПЕКТИВЫ
Захаров Владимир Владимирович, Яхно Николай Николаевич, Рейхарт Дмитрий Владимирович et al. · The Neurological Journal · 2013
The syndrome of mild cognitive impairment (MCI) with underlying chronic brain ischemia (“discirculatory encephalopathy”) is a clinical manifestation of neurodegenerative process, resulted from continuous activation of a number of pathophysiologic mechanisms. Three main mechanisms of neural tissue degradation can be emphasized as objects for neuroprotective effects: the excitotoxic pathway, the free radical pathway and the apoptosis-like pathway. Analysis of fundamental, pre-clinical and clinical studies suggests that the therapeutic strategy of MCI symptoms should be based on the approach, affecting all types of pathophysiological mechanisms. The paper considers memantine and melatonin as agents for simultaneous multi-targeted effect on different stages of MCI pathogenesis. Memantine reduces effects of excitotoxicity, while melatonin prevents free radical oxidation. It is logical to assume that reducing harmful effects of excitotoxicity and free radical stress factors should lead to the decrease of the amount of neurons with irreversible metabolic changes, in which apoptosis-like mechanisms leading to cell death are launched. The hypothesis of efficacy of memantine combined with melatonin was confirmed by the results of experimental studies on models of neurodegeneration. This inspires a hope for efficacy of combination of two neuroprotective drugs with different mechanisms of action as a basic treatment strategy for MCI syndrome, aimed on achieving more ambitious treatment goals than short symptomatic effect, and is the basis for development of a combined drug form for further testing in clinic.
Cited by 0 works.